Find Nerandomilast manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1423719-30-5, Bi 1015550, Bi-1015550, Nerandomilast [inn], I5dgt51ib8, Schembl25606332
Molecular Formula
C20H25ClN6O2S
Molecular Weight
449.0  g/mol
InChI Key
UHYCLWAANUGUMN-SSEXGKCCSA-N
FDA UNII
I5DGT51IB8

Nerandomilast
1 2D Structure

Nerandomilast

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[1-[[(5R)-2-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol
2.1.2 InChI
InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)/t30-/m1/s1
2.1.3 InChI Key
UHYCLWAANUGUMN-SSEXGKCCSA-N
2.2 Other Identifiers
2.2.1 UNII
I5DGT51IB8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (1-(((5r)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxo-6,7-dihydrothieno(3,2-d)pyrimidin-4-yl)amino)cyclobutyl)methanol

2. Bi 1015550

2.3.2 Depositor-Supplied Synonyms

1. 1423719-30-5

2. Bi 1015550

3. Bi-1015550

4. Nerandomilast [inn]

5. I5dgt51ib8

6. Schembl25606332

7. Gtpl12518

8. Glxc-27143

9. Ex-a7747

10. Da-61644

11. Bi1015550

12. Hy-153192

13. Cs-0654251

14. Bi-1015550?

15. (r)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide

16. [1-[[(5r)-2-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol

17. 1-[[(5r)-2-[4-(5-chloro-2-pyrimidinyl)-1-piperidinyl]-6,7-dihydro-5-oxidothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutanemethanol

18. Cyclobutanemethanol, 1-[[(5r)-2-[4-(5-chloro-2-pyrimidinyl)-1-piperidinyl]-6,7-dihydro-5-oxidothieno[3,2-d]pyrimidin-4-yl]amino]-

2.4 Create Date
2023-01-03
3 Chemical and Physical Properties
Molecular Weight 449.0 g/mol
Molecular Formula C20H25ClN6O2S
XLogP31.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count5
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area123
Heavy Atom Count30
Formal Charge0
Complexity624
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content

Nerandomilast

About the Company : Maithri Drugs Pvt. Ltd. is a trusted global partner in Active Pharmaceutical Ingredients (APIs), supplying to pharmaceutical leaders in 60+ countries. With APIs spanning antivirals...

Maithri Drugs Pvt. Ltd. is a trusted global partner in Active Pharmaceutical Ingredients (APIs), supplying to pharmaceutical leaders in 60+ countries. With APIs spanning antivirals, antibiotics, ARVs, CNS, and cardiovascular segments, we deliver innovation with reliability. Our facilities are approved by US FDA, EDQM, Health Canada, and WHO-GMP, backed by numerous global DMFs and recognition as an Ecovadis-rated company. Supported by strong R&D, global patents, and customer-centric practices, Maithri ensures world-class APIs with regulatory excellence and exceptional service.
Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Jascayd (Nerandomilast) is a small molecule drug candidate, which is currently being evaluated in Approved FDF clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Jascayd

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 09, 2025

blank

01

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : Jascayd (Nerandomilast) is a small molecule drug candidate, which is currently being evaluated in Approved FDF clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

Product Name : Jascayd

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 09, 2025

blank

Details:

Nerandomilast is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 01, 2025

blank

02

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : Nerandomilast is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 01, 2025

blank

Details:

Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


Lead Product(s): Nerandomilast,Carbamazepine

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 03, 2025

blank

03

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 03, 2025

blank

Details:

Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


Lead Product(s): Nerandomilast,Bosentan Hydrate

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 24, 2025

blank

04

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 24, 2025

blank

Details:

BI 1015550 (nerandomilast), an investigational oral, preferential inhibitor of PDE4B, in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, respectively.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 19, 2025

blank

05

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : BI 1015550 (nerandomilast), an investigational oral, preferential inhibitor of PDE4B, in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, respectively.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 19, 2025

blank

Details:

BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for progressive pulmonary fibrosis.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 10, 2025

blank

06

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for progressive pulmonary fibrosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 10, 2025

blank

Details:

BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for IPF.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 10, 2025

blank

07

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for IPF.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 10, 2025

blank

Details:

Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Diseases, Interstitial.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 04, 2025

blank

08

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Diseases, Interstitial.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 04, 2025

blank

Details:

Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 02, 2024

blank

09

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : Nerandomilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 02, 2024

blank

Details:

BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.


Lead Product(s): Nerandomilast,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 16, 2024

blank

10

Neuroscience
Not Confirmed
Neuroscience
Not Confirmed

Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 16, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1423719-30-5 / Nerandomilast API manufacturers, exporters & distributors?

Nerandomilast manufacturers, exporters & distributors 1

77

PharmaCompass offers a list of Nerandomilast API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nerandomilast manufacturer or Nerandomilast supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nerandomilast manufacturer or Nerandomilast supplier.

PharmaCompass also assists you with knowing the Nerandomilast API Price utilized in the formulation of products. Nerandomilast API Price is not always fixed or binding as the Nerandomilast Price is obtained through a variety of data sources. The Nerandomilast Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Nerandomilast

Synonyms

1423719-30-5, Bi 1015550, Bi-1015550, Nerandomilast [inn], I5dgt51ib8, Schembl25606332

Cas Number

1423719-30-5

Unique Ingredient Identifier (UNII)

I5DGT51IB8

Nerandomilast Manufacturers

A Nerandomilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nerandomilast, including repackagers and relabelers. The FDA regulates Nerandomilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nerandomilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Nerandomilast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Nerandomilast Suppliers

A Nerandomilast supplier is an individual or a company that provides Nerandomilast active pharmaceutical ingredient (API) or Nerandomilast finished formulations upon request. The Nerandomilast suppliers may include Nerandomilast API manufacturers, exporters, distributors and traders.

click here to find a list of Nerandomilast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Nerandomilast GMP

Nerandomilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Nerandomilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nerandomilast GMP manufacturer or Nerandomilast GMP API supplier for your needs.

Nerandomilast CoA

A Nerandomilast CoA (Certificate of Analysis) is a formal document that attests to Nerandomilast's compliance with Nerandomilast specifications and serves as a tool for batch-level quality control.

Nerandomilast CoA mostly includes findings from lab analyses of a specific batch. For each Nerandomilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Nerandomilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Nerandomilast EP), Nerandomilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nerandomilast USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty